Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Britannia Life SciencesFRA:L020 35 3-1 Month Momentum % is -20.31% as of Sep. 12, 2026. GuruFocus rates FRA:L020 with a GF Score™ of 35/100. The stock has 5 warning signs investors should review. Among 1,384 Biotechnology companies, Britannia Life Sciences ranks worse than 77.1% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-12), Britannia Life Sciences's 3-1 Month Momentum % is -20.31%.
The industry rank for Britannia Life Sciences's 3-1 Month Momentum % or its related term are showing as below:
FRA:L020's 3-1 Month Momentum % is ranked worse than 77.1% of 1384
companies
in the Biotechnology industry
Industry Median: 2.12
vs FRA:L020: -20.31
Britannia Life Sciences (FRA:L020) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Britannia Life Sciences 3-1 Month Momentum % Related Terms
FRA:L020 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Britannia Life Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Britannia Life Sciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Britannia Life Sciences's 3-1 Month Momentum % falls into.
Britannia Life Sciences (FRA:L020) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Britannia Life Sciences (FRA:L020) has a 3-1 Month Momentum % of -20.31% as of Sep. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Britannia Life Sciences and its competitors. According to the industry distribution chart, Britannia Life Sciences ranks #1067 out of 1384 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Britannia Life Sciences' 3-1 Month Momentum % too high?
Britannia Life Sciences' current 3-1 Month Momentum % is -20.31%. Based on the distribution chart, Britannia Life Sciences ranks #1067 out of 1384 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Britannia Life Sciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Britannia Life Sciences' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #1067 out of 1384 companies for 3-1 Month Momentum %. This places Britannia Life Sciences in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 2.12, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Britannia Life Sciences and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Britannia Life Sciences's current 3-1 Month Momentum % is -20.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (FRA:L020) has a current 3-1 Month Momentum % of -20.31%. The current 3-1 Month Momentum % is -20.31%. Britannia Life Sciences' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Britannia Life Sciences (FRA:L020), the current 3-1 Month Momentum % is -20.31% as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.
35GF Score
Get the complete analysis for FRA:L020
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:L020 has been successfully added to your 
